Azerbaijan vs Lower-middle income (World Bank): HIV-positive TB patients on ART (antiretroviral therapy)
Azerbaijan
100.0%
in 2024
Lower-middle income (World Bank)
95.0%
in 2024
Azerbaijan rank
1st
Lower-middle income (World Bank) rank
3rd
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Azerbaijan
- Lower-middle income (World Bank)
How they compare
Azerbaijan currently reports 100.0% against 95.0% in Lower-middle income (World Bank), a difference of 5.0%.
That makes Azerbaijan's figure about 1.1 times Lower-middle income (World Bank)'s.
The two have swapped places 4 times across 14 shared years of data; in 2011 it was Azerbaijan ahead.
Azerbaijan ranks 1st and Lower-middle income (World Bank) ranks 3rd of 144 countries.
Across the 2 decades both report, Azerbaijan averaged higher in 1 and Lower-middle income (World Bank) in 1.
Head to head by decade
| Decade | Azerbaijan | Lower-middle income (World Bank) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 73.8% | 79.3% | 5.6% | Lower-middle income (World Bank) |
| 2020s | 98.2% | 94.0% | 4.2% | Azerbaijan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Azerbaijan or Lower-middle income (World Bank)?
- Azerbaijan, at 100.0% against 95.0% in Lower-middle income (World Bank) as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Azerbaijan and Lower-middle income (World Bank)?
- 5.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Lower-middle income (World Bank)?
- 14 years are reported by both, from 2011 to 2024.
- How do Azerbaijan and Lower-middle income (World Bank) rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Azerbaijan ranks 1st and Lower-middle income (World Bank) ranks 3rd of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.